Analysis of the Benefit of Anti-PD-1 Monotherapy According to NGS-diagnosed Genetic Alterations in Patients with Non-small Cell Lung Cancer

Overview

Journal Explor Target Antitumor Ther

Specialty Oncology

Date 2025 Jan 7

PMID 39764418

Authors

Hortense De Saint Basile

Reza Elaidi

Zineb Maaradji

Helene Blons

Rym BenDhiab

Laure Gibault

Elizabeth Fabre

Affiliations

Soon will be listed here.

Abstract

Aim: Immune checkpoint inhibitors improved the survival of advanced non-small cell lung cancer. However, only 20% of patients respond to these treatments and the search for predictive biomarkers of response is still topical. The objective of this work is to analyze the anti-PD-1 monotherapy benefit based on genetic alterations diagnosed by next generation sequencing (NGS), in advanced non-small cell lung cancer.

Methods: Patients with advanced non-small cell lung cancer treated with immunotherapy were retrospectively included in this monocentric study. Clinical data, immunohistochemical expression of PD-L1 and molecular data, with a 22-genes NGS panel, were collected.

Results: 107 patients were included. The median age was 65 years [59; 73], 70 were men (65%), 96 had adenocarcinoma (90%), 33 were receiving a first line (31%). 54 patients had KRAS mutation (50%) and 56 had TP53 mutation (52%). The remaining mutations were present in fewer than 10 patients. There was no statistically significant differences in median of progression-free or overall survival based on KRAS-only, TP53-only or KRAS-TP53 mutations co-mutated compared to double wild-type patients ( = 0.46 and = 0.72 respectively).

Conclusions: The search for a predictive composite biomarker remains a major issue in the coming years.

References

Yang J, Gadgeel S, Sequist L, Wu C, Papadimitrakopoulou V, Su W . Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2018; 14(3):553-559. DOI: 10.1016/j.jtho.2018.11.028. View

Bayle A, Bonastre J, Chaltiel D, Latino N, Rouleau E, Peters S . ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. Ann Oncol. 2023; 34(10):934-945. DOI: 10.1016/j.annonc.2023.06.011. View

Yang J, Shepherd F, Kim D, Lee G, Lee J, Chang G . Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019; 14(5):933-939. DOI: 10.1016/j.jtho.2019.02.001. View

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J . , and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. Clin Cancer Res. 2018; 24(22):5710-5723. DOI: 10.1158/1078-0432.CCR-18-0163. View

Yang Y, Shen S, Sun Y, Husain H, Zhou H, Lu S . The relationship between different subtypes of and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. Transl Lung Cancer Res. 2022; 11(2):213-223. PMC: 8902092. DOI: 10.21037/tlcr-22-88. View

Guaitoli G, Tiseo M, Di Maio M, Friboulet L, Facchinetti F . Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2021; 10(6):2890-2916. PMC: 8264334. DOI: 10.21037/tlcr-20-941. View

Li D, Zhu X, Wang H, Li N . Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis. Eur J Surg Oncol. 2017; 43(7):1372-1379. DOI: 10.1016/j.ejso.2017.02.008. View

10.

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

11.

Lin A, Wei T, Meng H, Luo P, Zhang J . Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 2019; 18(1):139. PMC: 6745797. DOI: 10.1186/s12943-019-1062-7. View

12.

Kim J, Kim H, Kim B . Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. Oncotarget. 2017; 8(29):48248-48252. PMC: 5564642. DOI: 10.18632/oncotarget.17594. View

13.

Landre T, Justeau G, Assie J, Chouahnia K, Davoine C, Taleb C . Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2021; 71(3):719-726. PMC: 10992001. DOI: 10.1007/s00262-021-03031-1. View

14.

Kim J, Jung J, Kim K, Lee J, Im Y . TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors. Cancer Med. 2023; 12(11):12438-12451. PMC: 10278489. DOI: 10.1002/cam4.5953. View

15.

Aramini B, Banchelli F, Bettelli S, Manfredini S, DAmico R, Masciale V . Overall survival in patients with lung adenocarcinoma harboring "niche" mutations: an observational study. Oncotarget. 2020; 11(5):550-559. PMC: 7007296. DOI: 10.18632/oncotarget.27472. View

16.

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

17.

Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, Schnorbach J . KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. Br J Cancer. 2024; 131(3):524-533. PMC: 11300455. DOI: 10.1038/s41416-024-02746-z. View

18.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

19.

Sun L, Hsu M, Cohen R, Langer C, Mamtani R, Aggarwal C . Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JAMA Oncol. 2021; 7(6):937-939. PMC: 8050787. DOI: 10.1001/jamaoncol.2021.0546. View

20.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View